Cantor Fitzgerald Weighs in on Humacyte FY2026 Earnings

Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Humacyte in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will earn ($0.49) per share for the year. The consensus estimate for Humacyte's current full-year earnings is ($1.27) per share.

A number of other brokerages have also commented on HUMA. Wall Street Zen raised Humacyte from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. HC Wainwright started coverage on shares of Humacyte in a research note on Wednesday, May 14th. They set a "buy" rating and a $4.00 price target for the company. Benchmark dropped their price objective on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Finally, D. Boral Capital reissued a "buy" rating and set a $25.00 target price on shares of Humacyte in a research report on Monday. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Humacyte has a consensus rating of "Moderate Buy" and an average price target of $11.71.

Humacyte Stock Up 4.3%

HUMA traded up $0.11 during midday trading on Tuesday, hitting $2.67. The company had a trading volume of 4,760,054 shares, compared to its average volume of 3,829,788. The stock's 50 day moving average price is $1.81 and its 200 day moving average price is $3.19. Humacyte has a 52 week low of $1.15 and a 52 week high of $9.79. The company has a market capitalization of $414.17 million, a price-to-earnings ratio of -1.99 and a beta of 2.00.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.09. The business had revenue of $0.52 million for the quarter, compared to the consensus estimate of $0.46 million.

Hedge Funds Weigh In On Humacyte

Institutional investors and hedge funds have recently modified their holdings of the company. Columbia Advisory Partners LLC bought a new position in Humacyte in the 1st quarter worth $27,000. Hamilton Lane Advisors LLC bought a new position in Humacyte during the first quarter valued at approximately $37,000. Letko Brosseau & Associates Inc. bought a new position in shares of Humacyte during the 1st quarter valued at approximately $42,000. Vontobel Holding Ltd. purchased a new position in shares of Humacyte in the 4th quarter worth $50,000. Finally, Petros Family Wealth LLC bought a new stake in Humacyte during the fourth quarter worth approximately $50,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Humacyte

In other Humacyte news, Director Kathleen Sebelius acquired 50,000 shares of the business's stock in a transaction on Tuesday, April 8th. The shares were acquired at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the acquisition, the director now owns 91,207 shares in the company, valued at $120,393.24. This trade represents a 121.34% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Dale A. Sander purchased 20,000 shares of the stock in a transaction dated Thursday, April 10th. The stock was bought at an average cost of $1.53 per share, with a total value of $30,600.00. Following the transaction, the chief financial officer now owns 40,600 shares in the company, valued at $62,118. The trade was a 97.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 83,993 shares of company stock worth $118,224 over the last quarter. 5.10% of the stock is owned by corporate insiders.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.